Evidence map›Paper›PMID 40180018›Full record

ArticleFree radical biology & medicine2025

Mitochondrial and microtubule defects in Exfoliation Glaucoma.

Arunkumar Venkatesan, Marc Ridilla, Nileyma Castro, J Mario Wolosin, Jessica L Henty-Ridilla, Barry E Knox, Preethi S Ganapathy, Jamin S Brown, Anthony F DeVincentis Iii, Sandra Sieminski and 1 more

Abstract read
In one paragraph

Article in Free radical biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Crosstalk Between Allergic Inflammation and Autophagy.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Protein misfolding and mitochondrial dysfunction in glaucoma.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Arunkumar VenkatesanDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.
Marc RidillaFoundation for Prader-Willi Research, CA, USA.
Nileyma CastroDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USA; New York VA Health Care, Syracuse VA Medical Center, Syracuse, NY, USA.
J Mario WolosinEye and Vision Research Institute, Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica L Henty-RidillaDepartment of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA.
Barry E KnoxDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USA; Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA.
Preethi S GanapathyDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.
Jamin S BrownRetina-Vitreous Surgeons of Central New York, Syracuse, NY, USA.
Anthony F DeVincentis IiiEye Consultants of Syracuse, Syracuse, NY, USA.
Sandra SieminskiRoss Eye Institute, Buffalo, NY, USA.
Audrey M BernsteinDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, NY, USA; New York VA Health Care, Syracuse VA Medical Center, Syracuse, NY, USA; Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA.

Funding

Mechanisms of coordinated actin and microtubule dynamicsR35GM133485 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI Jessica L. Ridilla · 2019 to 2026
$3.3M
THE UBIQUITIN PATHWAY IN CORNEAL SCARRINGR01EY024942 · NEI · UPSTATE MEDICAL UNIVERSITY · PI AUDREY M BERNSTEIN · 2015 to 2026
$3.1M
A single dose anti-scarring therapeutic for the corneaR44EY035188 · NEI · DUB THERAPEUTICS INC. · PI WILLIAMS, TERE M. · 2023 to 2024
$1.8M
Cellular Dysfunction in Exfoliation GlaucomaR01EY030567 · NEI · UPSTATE MEDICAL UNIVERSITY · PI BERNSTEIN, AUDREY M, WOLOSIN, JOSE MARIO · 2020 to 2023
$1.6M
Investigating mechanosensation in the glaucomatous optic nerve headK08EY031755 · NEI · UPSTATE MEDICAL UNIVERSITY · PI GANAPATHY, PREETHI · 2021 to 2025
$1.1M
Optic nerve head cellular interactions in response to mechanical strain and fibrosisR21EY036198 · NEI · UPSTATE MEDICAL UNIVERSITY · PI GANAPATHY, PREETHI, MCDOWELL, COLLEEN MARY · 2024 to 2025
$447k
BLRD VA I01 BX005360NEI NIH HHS K08 EY031755NEI NIH HHS R01 EY024942NEI NIH HHS R01 EY030567NEI NIH HHS R21 EY036198NEI NIH HHS R44 EY035188NIGMS NIH HHS R35 GM133485
6 · The paper itself

Abstract

Exfoliation Syndrome is an age-related systemic condition characterized by large aggregated fibrillar material deposition in the anterior eye tissues. This aggregate formation and deposition on the aqueous humor outflow pathway are significant risk factors for developing Exfoliation Glaucoma (XFG). XFG is a multifactorial late-onset disease that shares common features of neurodegenerative diseases, such as increased protein aggregation, impaired protein degradation, and oxidative and cellular stress. XFG patients display decreased mitochondrial membrane potential and mitochondrial DNA deletions. Here, using Tenon Capsule Fibroblasts (TFs) from patients without glaucoma (No Glaucoma, NG) and XFG patients, we found that XFG TFs have impaired mitochondrial bioenergetics and increased reactive oxygen species accumulation. These defects are associated with mitochondrial abnormalities as XFG TFs exhibit smaller mitochondria that contain dysmorphic cristae, with increased mitochondrial localization to lysosomes and slowed mitophagic flux. Mitochondrial dysfunction in the XFG TFs was associated with hyperdynamic microtubules, decreased acetylated tubulin, and increased HDAC6 activity. Treatment of XFG TFs with a mitophagy inducer, Urolithin A (UA), and a mitochondrial biogenesis inducer, Nicotinamide Ribose (NR), improved mitochondrial bioenergetics and reduced ROS accumulation. Our results demonstrate that XFG TFs have abnormal mitochondria and suggest that mitophagy inducers may represent a potential class of therapeutics for reversing mitochondrial dysfunction in XFG patients.

Indexed as

Exfoliation SyndromeMicrotubulesMitochondriaAgedCells, CulturedEnergy MetabolismFemaleFibroblastsHistone Deacetylase 6HumansMaleMembrane Potential, MitochondrialMitophagyOxidative StressReactive Oxygen SpeciesHDAC6 protein, humanHistone Deacetylase 6Reactive Oxygen SpeciesExfoliation GlaucomaMicrotubule cytoskeletonMitochondriaMitophagyROSTenon fibroblast

Identifiers

PMID40180018
PMCPMC12074171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.